Continuous dopaminergic stimulation in early and advanced Parkinson's disease

Neurology

Volumn 62, Issue 1 SUPPL. 1, 2004, Pages

  Stocchi, Fabrizio ^a,c   Olanow, C Warren ^b   Brooks, ^d   Koller, ^d   Obeso, ^d   LeWitt, ^d   Jenner, ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4,6,6A,7,8,12B HEXAHYDRO 7 METHYLINDOLO[4,3 AB]PHENANTHRIDINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LISURIDE; NAXAGOLIDE; OXIDOPAMINE; QUINPIROLE; RACLOPRIDE; ROPINIROLE;

CLINICAL TRIAL; DOPAMINERGIC ACTIVITY; DRUG EFFECT; DRUG MIXTURE; DYSKINESIA; HUMAN; MONOTHERAPY; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

EID: 0345830746     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.62.1_suppl_1.s56     Document Type: Review

References (45)

1. Lang AE, Lozano AM. Parkinson's disease-first of two parts. New Engl J Med 1998;339:1044-1053.
2. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
3. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
4. Adler CH. Relevance of motor complications in Parkinson's disease. Neurology 2002;58(4 suppl 1):S51-56.
5. Nutt JG, Holford NH. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-573.
6. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990;40:340-345.
7. Stocchi F, Nordera G, Marsden CD. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 1997;20:95-115.
8. Colosimo C, De Michele M. Motor fluctuations in Parkinson's disease: pathophysiology and treatment. Eur J Neurol 1999;6:1-21.
9. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47(4 suppl 1):S2-9.
10. Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 1999;246:1127-1133.
11. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000;23(10 suppl):S2-7.
12. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000;55(11 suppl 4):S13-20.
13. Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci 2000;23(10 suppl):S117-126.
14. Calon F, Grondin R, Morissette M, et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol 2000;47(4 suppl 1):S70-78.
15. Filion M, Tremblay L, Bedard PJ. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991;547:152-161.
16. Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000;55(11 suppl 4):S72-77.
17. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 1990;525:36-44.
18. 11C]raclopride displacement and PET. Neurology 1996;46:1430-1436.
19. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55(suppl 1):1-9.
20. Olanow CW. The role of dopamine agonists in the treatment of early Parkinson's disease. Neurology 2002;58(4 suppl 1):S33-41.
21. Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998;13:234-241.
22. Hadj Tahar A, Gregoire L, Bangassoro E, Bedard PJ. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol 2000;23:195-202.
23. Maratos EC, Jackson MJ, Pearce RK, Jenner P. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Mov Disord 2001;16:631-641.
24. Gomez-Mancilla B, Bedard PJ. Effect of chronic treatment with(+)-PHNO, a D2 agonist in MPTP-treated monkeys. Exp Neurol 1992;117:185-188.
25. Gagnon C, Bedard PJ, Di Paolo T. Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. Eur J Pharmacol 1990;178:115-120.
26. Falardeau P, Bouchard S, Bedard PJ, Boucher R, Di Paolo T. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. Eur J Pharmacol 1988;150:59-66.
27. Montastruc JL, Rascol O, Senard JM, Rascol O. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
28. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
29. Jenner P, Al-Barghouthy G, Smith L, Kuoppamaki M, Jackson M, Rose S. Entacapone combined with L-dopa enhances antiparkinsonian activity and avoids dyskinesia in the MPTP-treated primate model of Parkinson's disease (PD). Mov Disord 2002;17(suppl 5):P146. Abstract.
30. Stocchi F, Vacca L, Berardelli A, De Pandis F, Ruggieri S. Long-duration effect and the postsynaptic compartment: study using a dopamine agonist with a short half-life. Mov Disord 2001;16:301-305.
31. Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in PD patients. Brain 2002;125:2058-2066.
32. Stocchi F, Berardelli A, Vacca L, et al. Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease. Clin Neuropharmacol 2003;26:151-155.
33. Stocchi F, Bramante L, Monge A, et al. Apomorphine and lisuride infusion. A comparative chronic study. Adv Neurol 1993;60:653-655.
34. Stocchi F, Vacca L, DePandis MF, Barbatol L, Valente M, Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 2001;22:93-94.
35. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-576.
36. Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23.
37. Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with on-off fluctuations. Neurology 1993;43:1698-1703.
38. Syed N, Murphy J, Zimmerman T Jr, Mark MH, Sage JI. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998;13:336-338.
39. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-17.
40. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
41. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. NOMECOMT Study Group. Neurology 1998;51:1309-1314.
42. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (CELOMEN study). Acta Neurol Scand 2002;105:245-255.
43. Brooks DJ, Sagar H, and the UK-IRISH Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease. A randomized, placebo-controlled, double-blind six-month study. J Neurol Neurosurg Psychiatry 2003;74:1064-1072.
44. Stocchi F, Grassini P, Onofrj M, et al. Is it possible to achieve continuous dopaminergic stimulation with oral levodopa doses plus entacapone? A pharmacokinetic study. Presented at 6th International Conference on Alzheimer's and Parkinson's disease (AD/PD 2003) which was held in Seville, Spain from May 8-12, 2003. Presented but not published.
45. Jenner P, Al-Barghouthy G, Smith L, Kuoppamaki M, Jackson M, Rose S, Olanow W. Initiation of entacapone with L-DOPA further improves antiparkinsonian activity and avoids dyskinesia in the MPTP primate model of Parkinson's disease. Neurology 2002;58(suppl 3):374-375.